There are currently 256 ongoing clinical trials involving Alzheimer's Disease
Of the 256 trials,103 trials are in Phase II
Furthermore, 60 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Alzheimer’s Disease, a Central Nervous System disorder. North America boasts the highest number of ongoing clinical trials involving Alzheimer’s Disease. Asia-Pacific and Europe are among some of the other prominent regions involved in Alzheimer’s Disease-related drug trials.
Eli Lilly and Co: The leading ongoing Alzheimer’s Disease-related clinical trials sponsor
Eli Lilly and Co, the United States of America-based pharmaceutical company, is the top sponsor for Alzheimer’s Disease-related ongoing clinical trials.
F. Hoffmann-La Roche Ltd, Eisai Co Ltd, Cognition Therapeutics Inc, Cassava Sciences Inc, and Johns Hopkins University are a few other notable sponsors involving Alzheimer’s Disease.
A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Alzheimer’s Disease
Donepezil hydrochloride (Aricep; Aricept; Donepezil; Eranz; Neuristor), and Memantine hydrochloride(Abixa; Axura; Ebix; Ebixa; Memantine Akatinol; Memantine Hydrochloride Daiich; Memantine Hydrochloride; Memantine; Memary; Namenda)are among the key marketed drugs involving Alzheimer’s Disease.
Donepezil hydrochloride (Aricep; Aricept; Donepezil; Eranz; Neuristor), an Acetylcholinesterase (Acetylcholine Hydrolase or Yt Blood Group or Apoptosis Related Acetylcholinesterase or ACHE or EC 3.1.1.7) Inhibitor, is indicated for the treatment of dementia of the Alzheimer’s type and Lewy body dementia. The drug is marketed in the United States of America, China, Japan, and the United Kingdom by Eisai Co Ltd. Donepezil hydrochloride was first approved in 1996 and formulated as film-coated tablets and tablets for the oral route of administration.
Memantine hydrochloride (Abixa; Axura; Ebix; Ebixa; Memantine Akatinol; Memantine Hydrochloride Daiich; Memantine Hydrochloride; Memantine; Memary; Namenda), a Glutamate Ionotropic Receptor NMDA Type Subunit (NMDAR or GRIN) Antagonist, is used to treat Alzheimer’s Disease, Dementia Associated With Alzheimer's Disease, and Vascular Dementias. The drug is marketed globally including the United States, Australia, France, Germany, and Japan by Merz Pharma GmbH & Co KgaA. Memantine hydrochloride was first approved in 2002 and is sold in the form of film-coated tablets, tablets, powder for solution and solution, and drops for oral administration.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward